Articles producció científica> Medicina i Cirurgia

CD200 genotype is associated with clinical outcome of patients with multiple myeloma

  • Identification data

    Identifier: imarina:9366466
    Authors:
    Gonzalez-Montes, YOsca-Gelis, GRodriguez-Romanos, RVillavicencio, AGonzález-Bártulos, MLlopis, FClapes, VOriol, ASureda, AEscoda, LSarrà, JGarzó, ALloveras, NGómez, BGranada, IGallardo, D
    Abstract:
    Immune dysfunction in patients with MM affects both the innate and adaptive immune system. Molecules involved in the immune response pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of immune checkpoint molecules in predicting the myeloma control and immunological scape as mechanism of disease progression. We retrospectively analyzed the clinical impact of the CD200 genotype (rs1131199 and rs2272022) in 291 patients with newly diagnosed MM. Patients with a CD200 rs1131199 GG genotype showed a median overall survival (OS) significantly lower than those with CC+CG genotype (67.8 months versus 94.4 months respectively; p: 0.022) maintaining significance in the multivariate analysis. This effect was specially detected in patients not receiving an autologous stem cell transplant (auto-SCT) (p < 0.001). In these patients the rs1131199 GG genotype negatively influenced in the mortality not related with the progression of MM (p: 0.02) mainly due to infections events.
  • Others:

    Author, as appears in the article.: Gonzalez-Montes, Y; Osca-Gelis, G; Rodriguez-Romanos, R; Villavicencio, A; González-Bártulos, M; Llopis, F; Clapes, V; Oriol, A; Sureda, A; Escoda, L; Sarrà, J; Garzó, A; Lloveras, N; Gómez, B; Granada, I; Gallardo, D
    Department: Medicina i Cirurgia
    URV's Author/s: Sarra Escarre, Jose
    Keywords: Bone marrow microenvironment Cd200 polymorphisms Disease Expression Genes Glycoprotein Immune checkpoint Immune disfunction Immunity Multiple myeloma Risk Susceptibility Therapeutic target
    Abstract: Immune dysfunction in patients with MM affects both the innate and adaptive immune system. Molecules involved in the immune response pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of immune checkpoint molecules in predicting the myeloma control and immunological scape as mechanism of disease progression. We retrospectively analyzed the clinical impact of the CD200 genotype (rs1131199 and rs2272022) in 291 patients with newly diagnosed MM. Patients with a CD200 rs1131199 GG genotype showed a median overall survival (OS) significantly lower than those with CC+CG genotype (67.8 months versus 94.4 months respectively; p: 0.022) maintaining significance in the multivariate analysis. This effect was specially detected in patients not receiving an autologous stem cell transplant (auto-SCT) (p < 0.001). In these patients the rs1131199 GG genotype negatively influenced in the mortality not related with the progression of MM (p: 0.02) mainly due to infections events.
    Thematic Areas: Biodiversidade Biotecnología Ciência de alimentos Ciências biológicas i Ciências biológicas ii Ciências biológicas iii Engenharias ii Engenharias iii Farmacia Immunology Immunology and allergy Interdisciplinar Medicina i Medicina ii Medicina iii Medicina veterinaria Nutrição Odontología Química Saúde coletiva Zootecnia / recursos pesqueiros
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: jose.sarra@urv.cat
    Record's date: 2024-05-23
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1252445/full
    Papper original source: Frontiers In Immunology. 15 1252445-
    APA: Gonzalez-Montes, Y; Osca-Gelis, G; Rodriguez-Romanos, R; Villavicencio, A; González-Bártulos, M; Llopis, F; Clapes, V; Oriol, A; Sureda, A; Escoda, L; (2024). CD200 genotype is associated with clinical outcome of patients with multiple myeloma. Frontiers In Immunology, 15(), 1252445-. DOI: 10.3389/fimmu.2024.1252445
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Article's DOI: 10.3389/fimmu.2024.1252445
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2024
    Publication Type: Journal Publications
  • Keywords:

    Immunology,Immunology and Allergy
    Bone marrow microenvironment
    Cd200 polymorphisms
    Disease
    Expression
    Genes
    Glycoprotein
    Immune checkpoint
    Immune disfunction
    Immunity
    Multiple myeloma
    Risk
    Susceptibility
    Therapeutic target
    Biodiversidade
    Biotecnología
    Ciência de alimentos
    Ciências biológicas i
    Ciências biológicas ii
    Ciências biológicas iii
    Engenharias ii
    Engenharias iii
    Farmacia
    Immunology
    Immunology and allergy
    Interdisciplinar
    Medicina i
    Medicina ii
    Medicina iii
    Medicina veterinaria
    Nutrição
    Odontología
    Química
    Saúde coletiva
    Zootecnia / recursos pesqueiros
  • Documents:

  • Cerca a google

    Search to google scholar